Stop chasing blockbusters. The money is hiding in the unloved orphan pipeline.
Most people in pharma still talk like its 2010: find the next blockbuster, win the next label, rinse and repeat. But the industry is quietly changingquietly enough that many…

Your regulatory team is not just preparing filings.
Its shaping the evidence that will either stand upor failwhen patent litigators step into the case.
Heres the uncomfortable truth: many regulatory decisions get made with a submission-first mindset. B…

Drug patent intelligence has a reputation problem.
In many organizations, it shows up lateusually when a team is already deep into formulation work, supplier selection, clinical planning, or partnership conversations. At that point, the story becomes f…

Most people think the hardest part of bringing a genericor next-in-classproduct to market is showing bioequivalence.
It isnt.
Bioequivalence is the easy part. Freedom to operate (FTO) is the cliff.
That sounds counterintuitive until youve lived through…

The Safe Patent Portfolio Trap: Why Minimal Filing Costs Are Quietly Rewriting Pharmas Growth Curve
Pharma has a new favorite phrase: build a safe patent portfolio. It sounds prudentdefensive, risk-managed, portfolio-lite. But behind the language of mi…

A $50 Million Notice Letter Isnt Just a Detail. Its a Business Model Failure.
In generic pharma, the difference between winning and losing often isnt a moleculeits a paragraph.
A recent DrugPatentWatch breakdown of a high-stakes Paragraph IV dispute sp…

Pharmaceutical launches are usually planned like engineering projects: timelines mapped, manufacturing validated, and risk models stress-tested.
Then a court enters the roomand the math suddenly turns into a question: Do you proceed, or do you wait?
Th…

Evergreening sounds like a conspiracyuntil you look at how drug patents actually stack up.
In theory, patent thickets are supposed to promote innovation: grant a time-limited right to profit, then make the knowledge public so competitors can bring safe…

Patent litigation isnt just about winningits about preventing expensive downstream loss.
That sounds obvious, but in pharma, its often ignored until its too late.
Consider the hidden ROI of an early challenge to a weak method-of-use drug patentthe ki…

The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money
In drug development, there are moments when the calendar looks like a promise. One of the biggest: 180-day exclusivity for certain first filers under the Hatch-Waxman framework. I…